Study of rBet v1 Tablets

Inclusion Criteria: * Symptomatic birch pollen-related allergic rhinoconjunctivitis for at least the last 2 pollen seasons * Sensitisation to birch pollen as demonstrated, at screening, by a positive SPT to birch pollen with wheal diameter greater than 3 mm and specific IgE levels \> 0.70 kU/L (birch pollen and rBet v 1) * Patients asymptomatic to all other allergens during the birch pollen season * RRTSS during the previous pollen season ≥ 12 out of a maximum possible score of 18 * Patients with an FEV1 ≥ 80% of the predicted value * Female patients with no childbearing potential * Female patients of childbearing potential are eligible if they are not sexually active or if they use a medically accepted contraceptive method and have a negative urine pregnancy test, and are willing and able to sign written informed consent stating that they will use appropriate contraception and not plan a pregnancy during this study * Patients able to be compliant with respect to the completion of the daily record card and taking of the investigational products * Patients having provided signed informed consent Exclusion Criteria: * Patients with symptoms of rhinoconjunctivitis during the birch pollen season due to non-birch-related allergens * Patients with symptomatic allergic rhinitis/rhinoconjunctivitis due to house dust mites * Patients with symptomatic allergic rhinitis/rhinoconjunctivitis due to cat or dog allergens, and living with these animals at home or at risk of frequent conta…